Trial Profile
A Non-Interventional Observational Study Assessing Safety of Deferasirox in Patients with Hemoglobinopathies and Transfusional Iron Overload: Results from the "Energy" Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2015
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Acronyms Energy
- 31 Jul 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.